Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
This bill requires coverage of annual lung cancer screening (per USPSTF recommendations) without prior authorization and, for Medicaid, without cost sharing.
It expands Medicaid coverage of counseling and pharmacotherapy for tobacco cessation to all Medicaid enrollees (including coverage of certain nonprescription drugs) and bars prior authorization for those services in Medicaid managed care contracts.
The bill extends the prohibition on prior authorization for annual lung cancer screening to Medicare Part B, Medicare Advantage plans, and group and individual private insurance plans.
As a targeted preventive‑care expansion with modest direct appropriations and patient‑focused features, the bill has a plausible path forward on substantive merits. However, it creates binding federal coverage and utilization rules across Medicaid, Medicare, and private plans that could draw opposition from insurers, state budget officials, and fiscal conservatives. Without broad bipartisan buy‑in or packaging into a larger health or appropriations bill, overcoming procedural hurdles—especially in the Senate—will be challenging.
Relative to its intended legislative type, this bill is a clearly structured substantive policy change that uses direct amendments to existing statutes to mandate coverage of annual lung cancer screening and expanded tobacco cessation services, eliminate prior authorization across major payer types, fund outreach, and require a GAO study. It is precise in statutory placement and effective-dating, and leverages USPSTF/Secretary guidance for clinical eligibility.
Removal of prior authorization: liberals see it as removing barriers; conservatives see it as limiting cost-control and quality management.
Removal of prior authorization: liberals see it as removing barriers; conservatives see it as limiting cost-control and quality management.
This persona is likely to view the bill favorably as a public-health measure that reduces financial and administrative barriers to an evidence-based cancer screen and expands access to tobacco cessation services for low-income people.
They will see no-cost screening in Medicaid and the elimination of prior authorization as equity and access improvements that can reduce mortality among high-risk populations.
The added outreach funding and a GAO study are seen as helpful steps to identify gaps and direct further action.
A centrist would generally favor prevention that reduces downstream costs and improves health outcomes but will look for evidence that removing prior authorization and expanding coverage is cost-effective and administrable.
They will appreciate the bill’s targeted outreach, sunsets for funding, and the GAO report, but want clarity on fiscal impact and safeguards against overuse.
They will also be attentive to state flexibility and implementation timelines.
This persona is likely to be skeptical of federal mandates that limit prior authorization and impose new coverage requirements across Medicaid, Medicare, and private plans.
They would worry about increased federal and state spending, reduced insurer tools to manage costs and quality, and potential federal encroachment on state flexibility and plan design.
They may support targeted prevention but prefer preserving prior authorization or state plan discretion.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
As a targeted preventive‑care expansion with modest direct appropriations and patient‑focused features, the bill has a plausible path forward on substantive merits. However, it creates binding federal coverage and utilization rules across Medicaid, Medicare, and private plans that could draw opposition from insurers, state budget officials, and fiscal conservatives. Without broad bipartisan buy‑in or packaging into a larger health or appropriations bill, overcoming procedural hurdles—especially in the Senate—will be challenging.
The bill has not accumulated any surfaced votes yet.
Removal of prior authorization: liberals see it as removing barriers; conservatives see it as limiting cost-control and quality management.
As a targeted preventive‑care expansion with modest direct appropriations and patient‑focused features, the bill has a plausible path forwa…
Relative to its intended legislative type, this bill is a clearly structured substantive policy change that uses direct amendments to existing statutes to mandate coverage of annual lung cancer screening and expanded to…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.